Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals Plc (CNTA)
:CNTA
RESEARCH TOOLSreports
CNTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.75 - $19.09
Previous CloseN/A
Volume658.98K
Average Volume (3M)808.27K
Market Cap
$2.14B
Enterprise Value$1.43B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 27, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding131,845,470
10 Day Avg. Volume1,229,221
30 Day Avg. Volume808,267
Standard Deviation0.18
R-Squared0.17
Alpha-0.00417
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)312.83
Price to Cash Flow (P/CF)-25.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit207.96
Enterprise Value/Ebitda-9.21
Forecast
1Y Price Target
$34.00Price Target Upside113.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Centessa Pharmaceuticals News
PremiumCompany Announcements
Centessa Pharmaceuticals Updates on OX2R Agonist Pipeline
PremiumCompany Announcements
Centessa Pharmaceuticals Secures $200 Million Loan Deal
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe recent acceleration of CNTA's lead candidate ORX750 into Phase II studies aims at establishing best-in-class safety, tolerability, and efficacy within the rare hypersomnia market.
Drug DevelopmentCNTA's rapidly advancing orexin pathway targeting franchise is viewed as meaningfully de-risked and potentially best in class.
Bears Say
Research And DevelopmentThe SerpinPC discontinuation facilitates company's laser focus on OX2R agonist franchise execution, also inclusive of more potent ORX142 and the new ORX489 progressing through IND-enabling studies to unlock sizeable market opportunities within broad array of CNS disorders.
---
Ownership Overview
0.82% Insiders
8.69% Mutual Funds
70.85% Other Institutional Investors
19.17% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTA FAQ
What was Centessa Pharmaceuticals Plc’s price range in the past 12 months?
Centessa Pharmaceuticals Plc lowest stock price was $7.75 and its highest was $19.09 in the past 12 months.
What is Centessa Pharmaceuticals Plc’s market cap?
Centessa Pharmaceuticals Plc’s market cap is $2.14B.
When is Centessa Pharmaceuticals Plc’s upcoming earnings report date?
Centessa Pharmaceuticals Plc’s upcoming earnings report date is Mar 27, 2025 which is in 34 days.
How were Centessa Pharmaceuticals Plc’s earnings last quarter?
Centessa Pharmaceuticals Plc released its earnings results on Nov 12, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.396 by $0.026.
Is Centessa Pharmaceuticals Plc overvalued?
According to Wall Street analysts Centessa Pharmaceuticals Plc’s price is currently Undervalued.
Does Centessa Pharmaceuticals Plc pay dividends?
Centessa Pharmaceuticals Plc does not currently pay dividends.
What is Centessa Pharmaceuticals Plc’s EPS estimate?
Centessa Pharmaceuticals Plc’s EPS estimate is -0.42.
How many shares outstanding does Centessa Pharmaceuticals Plc have?
Centessa Pharmaceuticals Plc has 131,845,470 shares outstanding.
What happened to Centessa Pharmaceuticals Plc’s price movement after its last earnings report?
Centessa Pharmaceuticals Plc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.396. Following the earnings report the stock price went up 1.614%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in CNTA
---
Centessa Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (113.70% Upside)
$34.00 (113.70% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.40%
12-Months-Change
Fundamentals
Return on Equity
-42.73%
Trailing 12-Months
Asset Growth
61.57%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals Plc
Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.
---
CNTA Stock 12 Month Forecast
Average Price Target
$34.00
▲(113.70% Upside)
Technical Analysis
Fate Therapeutics
―
Iovance Biotherapeutics
―
RAPT Therapeutics
―
Vir Biotechnology
―
ALX Oncology Holdings
―
Best Analysts Covering CNTA
1 Year
1 Year Success Rate
17/17 ratings generated profit
1 Year Average Return
+99.62%
reiterated a buy rating last month
Copying David Risinger's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +99.62% per trade.
---